Medical Research in Telangana

Peer-reviewed studies, clinical trials, and healthcare breakthroughs • Verified for Telangana

Phase-3 Completed • Approved for Clinical UseSource: The Lancet Oncology (May 2026 Edition)

AIIMS & ICMR Complete Landmark Multi-Center Trial on Indigenous CAR-T Cell Therapy for Blood Cancers

Institution: AIIMS New Delhi & IIT Bombay / ImmunoACT

The indigenously engineered NexCAR19 CAR-T cell therapy demonstrated an 82% complete response rate in relapsed B-cell lymphomas and leukemia at one-tenth the cost of international treatments.

Key Clinical Breakthroughs:

Engineered humanized T-cells directly seek and eliminate CD19 cancer antigens
Significantly reduced cytokine release syndrome (CRS) risk compared to first-generation therapies
Now made accessible across 14 apex government cancer institutes in India

🌟 Real-World Patient Impact: Life-saving immunotherapy brought within reach of Indian patients at ₹35-40 Lakhs compared to ₹3.5 Crore overseas.

Randomized Controlled Trial (1,200 Patients)Source: Indian Journal of Endocrinology and Metabolism

Continuous Glucose Monitoring (CGM) Linked to 1.8% HbA1c Reduction Without Medication Escalation in Indian Diabetics

Institution: Dr. Mohan's Diabetes Specialties Centre & NIMS Hyderabad

Real-time biofeedback from wearable CGM sensors enabled patients to observe immediate post-meal sugar spikes from high-glycemic carbohydrates, leading to lasting voluntary dietary adaptations.

Key Clinical Breakthroughs:

Patients eliminated hidden sugar sources like sweet bakery snacks and evening fruit juices
Time-in-Range (TIR 70-180 mg/dL) increased from 48% to 74% over 24 weeks
Significantly reduced nocturnal hypoglycemia episodes in patients on insulin

🌟 Real-World Patient Impact: Proves lifestyle self-correction through continuous biomarker tracking is as potent as adding a second-line antidiabetic drug.

Clinical Outcomes Study (450 Cases)Source: Journal of Thoracic and Cardiovascular Surgery

Robotic Single-Port Thoracic Surgery Shows 50% Reduction in Post-Operative Pain for Early Lung Cancer

Institution: Apollo Hospitals Institute of Robotic Surgery

Single-incision robotic lobectomy using 4th generation Da Vinci surgical arms through a 3.5cm intercostal opening achieved complete lymph node dissection with median hospital discharge in 48 hours.

Key Clinical Breakthroughs:

No rib spreading or muscle division required, drastically reducing chronic intercostal neuralgia
High-definition 3D 10x magnified visualization allows micro-vascular preservation
Patients returned to routine physical activity within 12 days versus 6 weeks for open thoracotomy

🌟 Real-World Patient Impact: Sets a new standard of surgical care for early-stage lung nodules and mediastinal tumors.